Posts

Showing posts with the label juniper publishers Reviews

Happy Easter- Juniper Publishers

Image
 

The Effect of Ramadan Fasting on Oral Anticoagulant: Experience of Tertiary Academic Hospital- Juniper Publishers

Image
  Juniper Publishers- Open Access Journal of Annals of Reviews & Research   The Effect of Ramadan Fasting on Oral Anticoagulant: Experience of Tertiary Academic Hospital- Juniper Publishers Authored by Fakhr AlAyoubi   Abstract Introduction:   Direct oral anticoagulants (DOACs) have been approved for stroke prevention in non-valvular atrial fibrillation (AF). The outcomes achieved by clinical trials depend on pharmacokinetics and pharmacodynamics of these drugs which are used orally in regular doses once or twice daily. During our routine practice we face an obligatory choice to prescribe NOAC twice daily during the month of Ramadan. Twice daily dose drugs in our practice as well as with Muslim patients everywhere in the world during the holy month of Ramadan. Objective:   to evaluate the effectiveness and safety of NOACs either once daily or twice daily used during the month of Ramadan for stroke prevention in Non-Valvular atrial fibrillation. Methods: ...

The Use of ActiGraft, an Autologous Skin Graft, in the Treatment of Complex Diabetes Foot Ulcer - A Case Study- Juniper Publishers

Image
Juniper Publishers- Open Access Journal of Annals of Reviews & Research     The Use of ActiGraft, an Autologous Skin Graft, in the Treatment of Complex Diabetes Foot Ulcer - A Case Study- Juniper Publishers Authored by Chinenye Wachuku Meng   Abstract Chronic Diabetic foot ulcers (DFUs) are a complication associated with many comorbidities that can result in limb amputation and even death. ActiGraft, an autologous blood clot tissue, showed to be effective in cutaneous hard to heal wounds by promoting the natural healing process of the wound. We present a case of an ActiGraft treatment, applied weekly for 3 weeks on a complicated case of DFU exhibiting extensive necrotic tissue, exposed bone, tendons and fascia. Blood was withdrawn from the patient, at the point-of-care, to create a blood clot that was then placed on the wound. ActiGraft treatment showed promotion of extensive granulation covering the exposed bone and tendon, reduction of necrotic tissue, ...

Bilateral Herpes Simplex Keratitis Presenting as Bilateral Ulcerative Blepharo-Keratoconjunctivitis: A Rarity or Pattern- Juniper Publishers

Image
Juniper Publishers- Open Access Journal of Annals of Reviews & Research   Bilateral Herpes Simplex Keratitis Presenting as Bilateral Ulcerative Blepharo-Keratoconjunctivitis: A Rarity or Pattern- Juniper Publishers   Authored by CharlesS Zwerling Abstract We report a case of an immunocompetent 77-year-old Caucasian female presenting with bilateral herpes simplex keratitis masquerading as bilateral ulcerative blepharo-keratoconjunctivitis. Most cases of herpes simplex keratitis present unilaterally and uncommon occurrences of bilateral cases range from 1.3% to 10.9%. In literature, bilateral herpes simplex keratitis has been reported for patients with atopic disease, corticosteroid use, autoimmune diseases, and UV A light exposure. Our patient had none of these conditions, but she did suffer from type 2 diabetes mellitus that was well-controlled. She had no prior history of known herpes simplex disease and tested negative for COVID 19. To date, this is the third...

Upcoming New Drug Therapies for Nocturia - A Nonsystematic Stepwise Review- Juniper Publishers

Image
  Juniper Publishers- Open Access Journal of Annals of Reviews & Research Upcoming New Drug Therapies for Nocturia - A Nonsystematic Stepwise Review- Juniper Publishers Authored by King C Lee Abstract Current treatment options for nocturia are unsatisfactory, prompting review of clinical studies of potential new and better drug therapies for nocturia. A 3-step nonsystematic review was performed. Step 1 was to review articles related to nocturia in multiple databases. Step 2 was to review articles identified in Step 1 for potential new and better drug therapies for nocturia. Step 3 was to review the websites of companies sponsoring new drug therapies. Two categories of potential new drugs were identified. Category 1 drugs include new drugs, new drug combinations, or new routes of administration of drugs that are in the existing class for nocturia. They are: (a) demospressin combined with tamsulosin (an alpha-1 blocker), solifenacin (an antimuscarinic), or furosemid...